Genetic mutations associated with pulmonary surfactant protein deficiency are associated with diverse clinical phenotypes. Mutations of the surfactant protein B and C genes were the first to be described. In 2004, fatal surfactant deficiency in newborns due to mutations of the gene encoding the adenosine triphosphate-binding cassette transporter A3 (ABCA3) was first reported. Few cases of lethal adenosine triphosphate-binding cassette transporter A3 mutations have been described to date. In our report, we describe a full-term newborn that died because of respiratory failure secondary to an uncommon ABCA3 genetic configuration.
Introduction
Pulmonary surfactant is a mixture of lipids and proteins that reduce surface tension at the air-liquid interface in the alveoli, preventing end-expiratory atelectasis. Mutations of the genes encoding surfactant proteins B and C are involved in surfactant deficiency and manifest with different clinical presentations. 1, 2 Mutations of the adenosine triphosphate-binding cassette transporter A3 (ABCA3) gene have been linked to fatal surfactant deficiency in newborns, 3, 4 but prolonged survival with chronic interstitial lung disease has also been observed in patients with ABCA3 mutations. 5 The ABCA3 protein is located in the limiting membrane of the lamellar bodies and has a key role in the production of surfactant. The incidence of fatal surfactant deficiency is not known, and only a few cases with ABCA3 mutations have been described to date (see Table 1 ).
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Case
We report the case of a full-term term male newborn delivered by cesarean section because of mild cardiotocographic alterations.
He was the first born of non-consanguineous healthy parents; the five minute Apgar score was 9, and birth weight was 3.36 kg. Within a few hours after birth, he developed mild respiratory distress treated with nasal continuous-positive air pressure. The first chest X-ray was normal. Nevertheless, respiratory distress and oxygen demands increased progressively; a chest X-ray performed 3 days later showed a diffuse reticular granularity. In all, 200 mg kg À1 of exogenous surfactant (Curosurf, Chiesi Farmaceutici, Parma, Italy) was administered with the INSURE (intubation/surfactant/ extubation) method with subsequent improvement of respiratory rate, chest retractions and X-ray findings. Nasal continuouspositive airway pressure support was discontinued and satisfactory respiratory activity was observed over the next 4 days. Thereafter, clinical and radiological signs of respiratory distress reoccurred and nasal continuous-positive air pressure support was restarted. Dexamethasone (0.2 mg kg À1 in two doses for 3 days, and 0.1 mg kg À1 once a day for 3 days) and furosemide (0.1 mg kg À1 for 3 days) was administered, but no benefits were observed. Several causes of respiratory distressFcystic fibrosis, primary ciliary dyskinesia, pulmonary hypertension, congenital heart diseases and infectionsFwere excluded. A blood sample was drawn to exclude genetic surfactant abnormalities. The chest X-ray worsened and a chest computed tomography scan showed groundglass opacity and septal thickening in all lung fields (Figure 1 ). Five additional doses of surfactant (200 mg kg À1 dose instead of the usual dose of 100 mg kg À1 dose considering the severity of the distress) were administered with the INSURE method, with improvements of progressively shorter duration and reduced amplitude. Moreover, dependency on oxygen and continuouspositive air pressure became more accentuated. When the newborn was 58 days old, in light of the frequent episodes of cyanosis, hypoxemia and the elevated oxygen requirements (FiO 2 between 0.60 and 0.90), he was intubated and mechanically ventilated. Three more doses of surfactant were administered, but little improvement in clinical status and chest X-ray was observed. Peak inspiratory pressure to maintain adequate oxygenation reached 40 to 45 cmH 2 O and FiO 2 1.0. Notwithstanding, he developed severe respiratory failure and died at the age of 72 days. Direct sequencing of SFPTB, SFPTC and ABCA3 was performed by methods previously reported. 8 No variants were identified in the SFTPB and SFTPC genes. In ABCA3, a compound heterozygosity for two new variants was found: the c.556C>A transition resulting in the p.Pro186Thr missense substitution in the putative protein and the c.2632delA, which results in a truncated protein (p.Met878Trpfs36X; reference ENST00000301732, numbering starting from ATG). Transmission of the identified variants from the parents was confirmed.
Discussion
Surfactant deficiency is a rare cause of respiratory distress in fullterm newborn infants. ABCA3 is the most recently described gene causing surfactant metabolism alterations. 3, 4 The incidence of this particular genetic deficiency is not known, and only a few cases have been described to date. In this study, we describe an additional ABCA3 genetic variation associated with progressive and fatal respiratory failure in a full-term infant. Clinical features were consistent with fatal surfactant deficiency and molecular results revealed the presence of two variants, transmitted from the healthy parents, which was consistent with mutations on different alleles.
Although we did not demonstrate that these variants represented the disease-causing mutation, several arguments support this possibility. The frameshift c.2632delA is predicted to result in a truncated protein 36 residues after codon 878 and frame-shift mutations are in general considered as having a high probability to be genuine mutations. For the missense p.Pro186Thr, we observed that the variant was absent in a sample of 134 alleles in the general population drawn from the same area of origin of the patient, thus it would not be a common variant. Moreover, there is a high degree of conservation of Pro186 between species (Rattus Norvegicus, Mus Musculus, Canis Familiaris and Zebrafish). Unfortunately, it was not possible to confirm molecular findings by lung tissue analysis. In fact, immunohistochemistry and ultrastructural evaluation may aid in the diagnosis, as characteristic abnormalities of lamellar bodies of alveolar type II cells may be observed by electron microscopy in ABCA3 deficiency. 4 This case report confirms the existence of an association between the molecular defect and surfactant protein deficiency, and underlines the importance of excluding this rare condition in fullterm neonates with persistent unexplained respiratory distress. Chest X-ray and computed tomography scan findings involving all lung fields, in addition to transient response to surfactant replacement therapy, may point to surfactant deficiency.
Until now, no therapies have been shown to slow the progression of the disease and even in our patient no benefits were observed with steroids, diuretics or surfactant administration. Lung transplantation has been suggested in patients with milder mutations, as well as in those who have survived to childhood or adulthood. Nevertheless, children affected by mutations often die within 3 months after birth. 9, 10 When diagnosis is confirmed, genetic counseling should be offered to parents. In this case, parents were carriers of ABCA3 gene mutations, which implies a 25% risk of conceiving a second child affected by the disease.
